ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER
Clinical trials for ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New triple therapy hopes to tame tough breast cancer
Disease control Recruiting nowThis study tests if a combination of three drugs (lenvatinib, pembrolizumab, and fulvestrant) is safe and works for people with ER-positive, HER2-negative breast cancer that has spread. About 54 adults whose cancer has not responded to other treatments will take part. The goal is…
Matched conditions: ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for breast cancer patients when first treatment fails
Disease control Recruiting nowThis study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break fr…
Matched conditions: ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Smart scan may help choose best breast cancer therapy
Knowledge-focused Recruiting nowThis study tests whether a special PET scan (EstroTEP) and blood tests can help doctors pick the best second-line treatment for people with ER-positive, HER2-negative metastatic breast cancer. About 300 participants will be assigned to either endocrine therapy or chemotherapy bas…
Matched conditions: ER POSITIVE/HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC